Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Vanda Pharmaceuticals is a specialty pharmaceutical company focused on central nervous system disorders, with two FDA-approved products: Hetlioz (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, and Fanapt (iloperidone) for schizophrenia. The company operates in a niche therapeutic area with limited competition but faces significant commercial execution challenges, evidenced by negative operating margins despite high gross margins, suggesting substantial R&D and SG&A spending relative to current revenue base.
Vanda generates revenue through direct sales of specialty pharmaceuticals targeting rare CNS disorders with limited treatment options. The 94% gross margin reflects typical pharmaceutical economics with low manufacturing costs relative to pricing. Pricing power derives from orphan drug designations and limited competition in Non-24 disorder treatment. The company likely employs a specialty sales force targeting sleep specialists, psychiatrists, and rare disease centers. Negative operating margins indicate the company is investing heavily in commercial infrastructure, R&D pipeline development, and regulatory activities that currently exceed revenue generation capacity.
Hetlioz prescription volume trends and market penetration in Non-24 and Smith-Magenis Syndrome patient populations
Clinical trial readouts for pipeline candidates or label expansion studies
FDA regulatory decisions on new drug applications or supplemental approvals
Reimbursement coverage decisions from major payers affecting product access
Partnership announcements or licensing deals that validate platform or provide non-dilutive funding
Cash runway concerns and potential financing events given negative cash flow profile
Orphan drug market size limitations - Non-24 disorder affects estimated 80,000-140,000 totally blind individuals in the US, creating a natural revenue ceiling that may not support current cost structure
Regulatory pathway complexity for CNS drugs requiring long-term safety data and potential FDA scrutiny on efficacy endpoints
Reimbursement environment for high-cost specialty drugs facing increasing payer pushback and prior authorization requirements
Patent cliff risk - loss of exclusivity on key products would enable generic competition and revenue erosion
Larger pharmaceutical companies developing competing therapies with greater commercial resources and established payer relationships
Alternative treatment modalities including behavioral interventions or off-label use of existing drugs reducing addressable market
Schizophrenia market (Fanapt) is highly competitive with multiple generic and branded antipsychotics offering similar efficacy profiles
Cash burn rate of approximately $100M annually (negative operating cash flow) creates financing risk if revenue growth does not accelerate
Current ratio of 2.39 provides near-term liquidity buffer but runway may be limited to 12-18 months at current burn rate depending on cash balance
Equity dilution risk if company needs to raise capital through secondary offerings to fund operations
Negative ROE (-49.2%) and ROA (-59.3%) indicate value destruction at current operational performance levels
low - Specialty pharmaceuticals for rare diseases and chronic psychiatric conditions exhibit minimal correlation to GDP or economic cycles. Patients with Non-24 disorder or schizophrenia require continuous treatment regardless of economic conditions. However, commercial insurance coverage and patient affordability programs may face pressure during recessions, potentially affecting prescription fulfillment rates.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting biotech stocks trading on future earnings potential rather than current cash flows. (2) Cash investments generate higher yields, partially offsetting operating losses, but this benefit is minor relative to valuation compression. The company's minimal debt (0.05 D/E) eliminates refinancing risk.
Minimal direct credit exposure. The company does not operate a lending business or carry significant receivables risk. However, tightening credit conditions could affect: (1) Ability to raise capital if additional financing is needed given negative cash flow, (2) Hospital and pharmacy payment cycles if healthcare providers face liquidity constraints, (3) Patient access if insurance coverage becomes more restrictive during economic stress.
growth/speculative - The stock attracts investors focused on turnaround potential and pipeline optionality rather than current profitability. Negative margins and cash flow eliminate value and dividend investors. The 35% one-year return suggests momentum traders have participated. Typical holders include biotech-focused funds, special situations investors betting on commercial inflection, and retail investors attracted to small-cap healthcare volatility. The low market cap ($400M) and negative earnings create significant volatility and limit institutional ownership.
high - Small-cap biotechnology stocks with negative earnings exhibit elevated volatility driven by binary clinical/regulatory events, financing announcements, and sector rotation. Limited float and institutional ownership amplify price swings. Recent 32-35% six-month and one-year returns indicate substantial price momentum but also reflect high beta to biotech sector sentiment.
